399 Sarcoma Clinical Trials Recruiting Now (May 2026): Soft Tissue + Bone, IO, Cell Therapy, GIST, IDH1+ Chondrosarcoma

Last updated: May 18, 2026

Current Clinical Trial Landscape

Sarcoma subtypes:

Soft tissue sarcoma — leiomyosarcoma, liposarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma
Bone sarcoma — osteosarcoma (most common in children/young adults), Ewing sarcoma, chondrosarcoma
GIST — gastrointestinal stromal tumor, including KIT/PDGFRA wild-type and SDH-deficient subsets
Synovial sarcoma — uniquely amenable to NY-ESO-1 and MAGE-A4 TCR-T cell therapy when biomarker-positive

Active research areas in 2026:

Biomarker-selected Phase 3: ivosidenib for IDH1+ chondrosarcoma, olverembatinib for SDH-deficient GIST
TCR-T cell therapy: NY-ESO-1 (mipetresgene autoleucel) and MAGE-A4 (afamitresgene autoleucel) for synovial sarcoma
Immunotherapy + chemotherapy combinations in advanced soft tissue sarcoma (DDLPS, UPS)
Chemotherapy combinations (doxorubicin/ifosfamide/gemcitabine backbones)
Targeted therapies (MDM2 in liposarcoma, CDK4/6, FGFR, tyrosine kinases)
Neoadjuvant/perioperative approaches including hyperthermia and immune-radiation combinations

Standard of care: Localized soft tissue/bone: surgery ± radiation. Metastatic soft tissue 1L: doxorubicin-based chemotherapy. Osteosarcoma: MAP (methotrexate, doxorubicin, cisplatin). GIST 1L: imatinib (KIT/PDGFRA-driven); sunitinib then regorafenib on progression; ripretinib in 4L+; avapritinib for PDGFRA D842V. Advanced chondrosarcoma: largely chemotherapy-resistant; IDH1 inhibition is the first targeted approach.

Recruiting Trials by Treatment Setting

Localized / Neoadjuvant

Before or alongside surgery for localized disease:

NCT06835049 - Total neoadjuvant treatment with hyperthermia in high-risk soft tissue sarcoma
NCT06492954 - Atezolizumab + SBRT + surgery
NCT07049848 - SATURN-STS: neoadjuvant atezolizumab + doxorubicin with concurrent preoperative radiation (Phase 2)

First-Line Metastatic

For previously untreated advanced/metastatic sarcoma (and newly diagnosed osteosarcoma):

NCT04605770 - Pemetrexed + cisplatin in soft tissue sarcoma
NCT07359053 - MAGNATE-S: paclitaxel polymer micelles combination in advanced sarcoma
NCT06422806 - Immunotherapy + chemotherapy vs chemotherapy alone in advanced dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma (Phase 3)
NCT06669013 - Chemo-immunotherapy in patients under 18 with bone and soft tissue sarcomas (Phase 3 pediatric)
NCT05691478 - Cabozantinib added to chemotherapy in newly diagnosed osteosarcoma (Phase 3)

Second-Line / Refractory

After progression on first-line therapy:

NCT06389799 - Pemigatinib + retifanlimab in dedifferentiated liposarcoma
NCT06171282 - Oncolytic virus (R130) for advanced bone/soft tissue sarcoma
NCT07062003 - Minibeam radiation therapy for recurrent sarcoma
NCT07516925 - Ivonescimab (PD-1/VEGF bispecific) in leiomyosarcoma (Phase 2)

Biomarker-Selected Phase 3

Histology + biomarker entry requirement. These trials require specific molecular testing before screening:

NCT06127407 - Ivosidenib (Tibsovo) in IDH1-mutated locally advanced or metastatic conventional chondrosarcoma. First targeted therapy approach in chondrosarcoma, which is historically chemoresistant.
NCT06640361 - Olverembatinib in SDH-deficient GIST. Addresses a long-standing therapy gap — SDH-deficient GIST does not respond to imatinib because it lacks KIT/PDGFRA driver mutations.

Cell Therapy & TCR-T

Engineered T-cell therapies targeting intracellular tumor antigens via TCR (distinct from CAR-T which targets cell-surface antigens). Requires HLA typing and tumor antigen expression testing:

NCT07174427 - Mipetresgene autoleucel (TBI-1301, Mip-cel) — NY-ESO-1 TCR-T in NY-ESO-1+ synovial sarcoma (Phase 3). Follows the 2024 FDA approval of afamitresgene autoleucel (MAGE-A4 TCR-T, Tecelra) for advanced synovial sarcoma.

GIST-Specific

Gastrointestinal stromal tumor (KIT/PDGFRA-mutant or wild-type/SDH-deficient). Trial selection depends on prior TKI history:

NCT06640361 - Olverembatinib in SDH-deficient GIST (Phase 3, listed above under biomarker-selected)
NCT07406633 - KQB198 + imatinib in 1L advanced/metastatic GIST (Phase 2)
NCT05009927 - Continuing vs discontinuing imatinib after 10 years in GIST (Phase 2)

Trials by Sarcoma Subtype

Soft Tissue Sarcoma

Includes leiomyosarcoma, liposarcoma (dedifferentiated, well-differentiated, myxoid/round cell), synovial sarcoma, undifferentiated pleomorphic sarcoma, angiosarcoma, and others. View all →

Bone Sarcoma (Osteosarcoma, Ewing, Chondrosarcoma)

Osteosarcoma is the most common primary bone cancer (adolescents/young adults; MAP regimen + surgery is standard). Ewing sarcoma carries the EWSR1 translocation (pediatric/young adult). Chondrosarcoma is historically chemoresistant; IDH1 inhibition (ivosidenib, NCT06127407 above) is the first targeted approach. View all →

GIST

Gastrointestinal stromal tumor — KIT/PDGFRA-mutant (responsive to imatinib, sunitinib, regorafenib, ripretinib, avapritinib) or SDH-deficient (gap in approved therapy; addressed by NCT06640361 olverembatinib Phase 3 above). See also our dedicated GIST trials page. View all →

Trials by Treatment Approach

Checkpoint Inhibitors & Immunotherapy

Immunotherapy shows variable activity across sarcoma subtypes; combinations with chemotherapy or radiation are being explored to broaden responder populations. Notable: NCT06422806 Phase 3 IO + chemo in DDLPS/UPS, NCT06669013 Phase 3 pediatric chemo-immunotherapy, NCT07049848 SATURN-STS neoadjuvant atezolizumab. View all →

Chemotherapy

Doxorubicin, ifosfamide, gemcitabine/docetaxel, and other agents remain the backbone of treatment. View all →

Targeted Therapy

MDM2 inhibitors (liposarcoma), CDK4/6 inhibitors, FGFR inhibitors, IDH1 inhibitors (chondrosarcoma), and KIT/PDGFRA inhibitors (GIST).

NCT06389799 - Pemigatinib (FGFR inhibitor) + retifanlimab in dedifferentiated liposarcoma
NCT06127407 - Ivosidenib (IDH1 inhibitor) in IDH1+ chondrosarcoma (Phase 3)

Frequently Asked Questions

How do I find sarcoma clinical trials I'm eligible for?

Paste your medical summary into ClinTrialFinder to get AI-matched sarcoma trials in minutes. The tool considers your sarcoma subtype, tumor grade, and treatment history across all soft tissue and bone sarcomas.

What sarcoma trials are currently recruiting?

There are 399 recruiting interventional sarcoma trials (May 2026) including 19 Phase 3 studies. Notable Phase 3 trials include ivosidenib for IDH1-mutated chondrosarcoma, olverembatinib for SDH-deficient GIST, mipetresgene autoleucel (NY-ESO-1 TCR-T) for synovial sarcoma, and immunotherapy plus chemotherapy in advanced dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma.

Are there cell therapy or TCR-T trials for synovial sarcoma?

Yes. Mipetresgene autoleucel (TBI-1301) is in Phase 3 for NY-ESO-1 positive synovial sarcoma (NCT07174427), following the 2024 FDA approval of afamitresgene autoleucel (MAGE-A4 TCR-T, Tecelra). Eligibility requires both a specific HLA type and the corresponding tumor antigen expression on biopsy. TCR-T differs from CAR-T in that it targets intracellular antigens via T-cell receptors, whereas CAR-T targets cell-surface antigens.

What new Phase 3 sarcoma trials opened in 2025-2026?

Key recent Phase 3 trials include ivosidenib in IDH1-mutated chondrosarcoma (NCT06127407), olverembatinib in SDH-deficient GIST (NCT06640361, addressing a long-standing therapeutic gap), TBI-1301 NY-ESO-1 TCR-T in synovial sarcoma (NCT07174427), pediatric chemo-immunotherapy in bone/soft tissue sarcoma (NCT06669013), and immunotherapy + chemotherapy vs chemotherapy alone in advanced dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma (NCT06422806).

Find Sarcoma Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific sarcoma subtype and treatment history.

Find Matching Trials